



Joint Action  
Antimicrobial Resistance and  
Healthcare-Associated Infections



Co-funded by the  
Health Programme  
of the European Union

One Health national strategies and  
national action plans for AMR in Europe

# Work Package 5

## Results Self-Assessments

Marcel de Kort  
Ministry of Health, Welfare and Sport  
The Netherlands




The overall objective of EU-JAMRAI is...

- Coordinate policies for the control of AMR and HCAI
- Implement policies across EU Member States
- In alignment with other initiatives (ECDC and WHO)

How?

By bringing together different networks => policymakers, experts and others, working in European and International initiatives relevant for policy decision.

# Objective Work Package 5




The overall objective of Work Package 5 is...

... to support Member States on the implementation of the

*Council Conclusions on the next steps under a  
One Health approach to combat AMR (2016).*

→ **Have in place by mid-2017 a National Action Plan based on the One Health approach**

# Main steps of Work Package 5



## YEAR 1


1. mapping of national strategies and action plans
2. self-assessment tool
3. analysis of self-assessments and SWOT's

## YEAR 2-3


4. country-to-country assessments
5. strengthening supervision

## Participants of Mapping of National Action Plans

- non-WP5 participants
- WP5 participants




# Results Self-Assessment- TEN TOPICS



1. How to KEEP AMR on political agenda
2. How to GET AMR on the agenda
3. Tackling AMR in all domains; setting priorities
4. How does the One Health approach work in practice?
5. EU data are used to put national data in perspective - BUT difficult to interpret and translate surveillance data into action for policy makers and politicians

# Results Self-Assessment- TEN TOPICS



6. Responsibilities at different levels and sectors
7. Different experiences with working with measurable goals
8. Several countries have shown that policy measures work in reducing AMR (MRSA)
9. Many actions taken showing hopeful results and good practices  
- but overall EU resistance levels and antibiotic use worsen (as shown by ECDC).

## 10. Veterinary domain

- Noteworthy differences between countries. Forerunners: SE, FR, DE, NL
- Best practices are perceived useful
- Collection of sales and ab use data is useful but difficult, especially per animal species.
- Political pressure helps set up an infrastructure for surveillance, cooperation between stakeholders and domains etc.
  - Clear difference between SE, FR, DE, NL & PL, SL, CZ.




# What's next?



“The country-to-country assessment will allow representatives of WP5 participating countries to **evaluate** each other’s NAPs and One Health strategies, **reflect** about policy options and provide recommendations to **support** countries on the development and implementation of the NAP.”


*Grant Agreement*

# Schedule country-to-country visits



| Visiting country | Receiving country | Planning               |
|------------------|-------------------|------------------------|
| Germany          | France            | 8-10 Oct 2018 (pilot)  |
| Slovenia         | Czech Republic    | 24-26 Oct 2018 (pilot) |
| Netherlands      | Spain             | 26-29 Nov 2018 (pilot) |
| Sweden           | Slovenia          | 15-17 April 2019       |
| France           | Poland            | 27-29 May 2019         |
| Romania          | Greece            | 19-21 June 2019        |
| Italy            | Netherlands       | Week 27 (1-5 July)     |
| Greece           | Germany           | 2-6 Sept 2019          |
| Poland           | Italy             | 18-20 Sept 2019        |
| Lithuania        | Romania           | 23-26 Sept 2019        |
| Czech Republic   | Belgium           | 14-16 Oct 2019         |
| Spain            | Sweden            | 14-17 Oct 2019         |
| Belgium          | Lithuania         | 25-27 Nov 2019         |

# Minimal requirements country-to-country assessments



- Incoming team of *at least* three people:
  - policymaker human domain
  - policymaker veterinary domain
  - one subject matter expert
- Length of visit:  $\geq 3$  days
- One Health aspect covered
- Wrap-up meeting with national authorities at the end of the visit to present preliminary outcome of the visit

# Thank you!

Contact: [m.d.kort@minvws.nl](mailto:m.d.kort@minvws.nl)

EU-JAMRAI



Joint Action  
Antimicrobial Resistance and  
Healthcare-Associated Infections



Co-funded by the  
Health Programme  
of the European Union

*\* This presentation arises from the Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), which has received funding from the European Union in the framework of the Health Program (2014-2020) under the Grant Agreement N° 761296. Sole responsibility lies with the author and the Consumers, Health, Agriculture and Food Executive Agency is not responsible for any use that may be made of in the information contained therein.*